Published Paper Details:

Prostate cancer stands out as one of the most intricate forms of cancer and is the foremost cause of death among men. Due to cellular heterogeneity and variation in Androgen receptor expression diagnosis and treatment of Prostate cancer is very challenging. Most of the chemotherapeutic agents have been developed to block binding and inhibit the synthesis of Androgen. However, long-term use of Androgen deprivation therapy leads to resistant prostate cancer. Metformin is a biguanide which is the most commonly prescribed drug for T2DM. It lowers glucose levels through AMPK activation, subsequently affecting the mTOR pathway and additionally inhibiting the PI3K/Akt by regulation of PIP3. Hence, Metformin may be an important molecule in the case of heterogeneity of AR signalling where it might influence AMPK and mTOR pathway. In this paper we have evaluated the efficacy of metformin in presence or absence of AR or its variant. The study involves three different cell lines:1) Lncap cells with an AR receptor,2) 22RV-1 cells with an AR and its variant, and 3) PC3 cells, an AR-negative cell line. We investigated the Inhibitory activity of metformin in these cell lines in the context of AR. and its variant ARV7. Moreover, the influence of Synthetic androgen R1881 was also explored.